UC2AR081029
Cooperative Agreement
Overview
Grant Description
Ellipss: Elucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium - Abstract
Psoriatic Spectrum Diseases (PSD) affect over 8 million individuals in the U.S. living with Psoriasis (PSO) or Psoriatic Arthritis (PSA). These diseases encompass heterogeneous phenotypes, ranging from plaque, guttate, palmoplantar, inverse, pustular, and erythrodermic forms of psoriasis, to synovial, entheseal, and axial forms of PSA.
Here, we assembled a world-class multidisciplinary team of scientists in PSD cohort assembly, clinical phenotyping, biosample acquisition, pathology, statistics, and bioinformatics for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) PSD Disease Teams (DTS).
The major scientific goals of the PSD DT are to understand the cellular and molecular composition of distinct PSD endotypes and how they link with phenotypes, to identify how key pathogenic or regulatory cells spatially interact with each other and with environmental cues (i.e., microbiome), and to define at a single-cell level how the transition to PSA unfolds in the setting of PSO.
To accomplish the goals of the PSD AMP, we propose the creation of the Ellipss (Elucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium) Disease Team (DT). The aims of the Ellipss team are to:
1) Enroll diverse PSD cohorts and perform clinical phenotyping, data capture, and tissue collection.
2) Implement an effective management plan for the Ellipss multidisciplinary team.
3) Optimize the interface of the Ellipss team with the AMP-AIM network.
Lastly, a robust Opportunities Fund (OF) management program is proposed under the direction and leadership of Dr. James T. Elder at the University of Michigan. The Ellipss PSD DT will efficiently integrate with the AMP AIM network, facilitate the collection of PSD biosamples, and help provide an unprecedented view of cell types and states, along with spatial and tissue interactions (skin, joint, blood, microbiome) to deconstruct/reconstruct the psoriatic disease spectrum.
Psoriatic Spectrum Diseases (PSD) affect over 8 million individuals in the U.S. living with Psoriasis (PSO) or Psoriatic Arthritis (PSA). These diseases encompass heterogeneous phenotypes, ranging from plaque, guttate, palmoplantar, inverse, pustular, and erythrodermic forms of psoriasis, to synovial, entheseal, and axial forms of PSA.
Here, we assembled a world-class multidisciplinary team of scientists in PSD cohort assembly, clinical phenotyping, biosample acquisition, pathology, statistics, and bioinformatics for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) PSD Disease Teams (DTS).
The major scientific goals of the PSD DT are to understand the cellular and molecular composition of distinct PSD endotypes and how they link with phenotypes, to identify how key pathogenic or regulatory cells spatially interact with each other and with environmental cues (i.e., microbiome), and to define at a single-cell level how the transition to PSA unfolds in the setting of PSO.
To accomplish the goals of the PSD AMP, we propose the creation of the Ellipss (Elucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium) Disease Team (DT). The aims of the Ellipss team are to:
1) Enroll diverse PSD cohorts and perform clinical phenotyping, data capture, and tissue collection.
2) Implement an effective management plan for the Ellipss multidisciplinary team.
3) Optimize the interface of the Ellipss team with the AMP-AIM network.
Lastly, a robust Opportunities Fund (OF) management program is proposed under the direction and leadership of Dr. James T. Elder at the University of Michigan. The Ellipss PSD DT will efficiently integrate with the AMP AIM network, facilitate the collection of PSD biosamples, and help provide an unprecedented view of cell types and states, along with spatial and tissue interactions (skin, joint, blood, microbiome) to deconstruct/reconstruct the psoriatic disease spectrum.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Funding Agency
Place of Performance
Rochester,
New York
146113847
United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 1490% from $500,002 to $7,948,120.
University Of Rochester was awarded
Immunoendotypes in Psoriatic Skin & Synovium: Ellipss Grant
Cooperative Agreement UC2AR081029
worth $7,948,120
from National Eye Institute in March 2022 with work to be completed primarily in Rochester New York United States.
The grant
has a duration of 4 years 9 months and
was awarded through assistance program 93.855 Allergy and Infectious Diseases Research.
The Cooperative Agreement was awarded through grant opportunity Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/21/26
Period of Performance
3/21/22
Start Date
12/31/26
End Date
Funding Split
$7.9M
Federal Obligation
$0.0
Non-Federal Obligation
$7.9M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for UC2AR081029
Transaction History
Modifications to UC2AR081029
Additional Detail
Award ID FAIN
UC2AR081029
SAI Number
UC2AR081029-3887991937
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NB00 NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases
Funding Office
75NW00 NIH National Eye Institute
Awardee UEI
F27KDXZMF9Y8
Awardee CAGE
03CZ7
Performance District
NY-25
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institutes of Health Conditional Gift Fund, Health and Human Services (075-8253) | Health care services | Grants, subsidies, and contributions (41.0) | $1,700,002 | 63% |
| National Institute of Allergy and Infectious Diseases, National Institutes of Health, Health and Human Services (075-0885) | Health research and training | Grants, subsidies, and contributions (41.0) | $400,000 | 15% |
| National Eye Institute, National Institutes of Health, Health and Human Services (075-0887) | Health research and training | Grants, subsidies, and contributions (41.0) | $400,000 | 15% |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Health and Human Services (075-0888) | Health research and training | Grants, subsidies, and contributions (41.0) | $200,000 | 7% |
Modified: 9/21/26